Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CET

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
08:01a GLAXOSMITHKLINE : GSK Submits Landmark IMPACT Data to US Regulatory Authority to..
11/22 GLAXOSMITHKLINE PLC : (GSK) Shares Bought by Comerica Bank
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/22 GLAXOSMITHKLINE : ViiV Juluca approved in US as first 2-drug regimen
11/21 GLAXOSMITHKLINE : Findings on Biomimetics Reported by Investigators at GlaxoSmit..
11/21 GLAXOSMITHKLINE : Data on Sulfonamides Detailed by Researchers at GlaxoSmithKlin..
11/21 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc in the Area of Colitis Repor..
11/21 GLAXOSMITHKLINE : GSK publishes 2018 dividend dates
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimizes likely staff losses
More news
News from SeekingAlpha
11/22 GILEAD : Buying New Growth
11/22 YOUR DAILY PHARMA SCOOP : Teva Valuation, DelMar Lead Candidate, Galapagos Comme..
11/21 'Safer' Dividend Follower Favorites Leader Is Spark Energy, As Per November G..
11/21 Followers Find Frontier Tops By Broker Target Gains & Yield For November
11/21 FDA OKs ViiV Healthcare's two-drug combo for HIV-1
Financials ( GBP)
Sales 2017 30 089 M
EBIT 2017 8 449 M
Net income 2017 3 716 M
Debt 2017 14 279 M
Yield 2017 6,14%
P/E ratio 2017 18,24
P/E ratio 2018 14,74
EV / Sales 2017 2,60x
EV / Sales 2018 2,56x
Capitalization 64 066 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,7  GBP
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-16.61%85 349
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
MERCK AND COMPANY-6.23%148 014